Related references
Note: Only part of the references are listed.Expression of the neural cell adhesion molecule (CD56) by human myeloma cells
J. DRACH et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Blockade of natural killer cell-mediated lysis by NCAM140 expressed on tumor cells
Mostafa Jarahian et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
The generation and regulation of functional diversity of malignant plasma cells
Liat Nadav et al.
CANCER RESEARCH (2006)
Role for interleukin-6 and insulin-like growth factor-I via PI3-K/Akt pathway in the proliferation of CD56- and CD56+ multiple myeloma cells
Naohi Sahara et al.
EXPERIMENTAL HEMATOLOGY (2006)
Prognostic relevance of CD56 expression in multiple myeloma: A study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant
H Chang et al.
LEUKEMIA & LYMPHOMA (2006)
Both heterozygous and homozygous α+ thalassemias protect against severe and fatal Plasmodium falciparum malaria on the coast of Kenya
TN Williams et al.
BLOOD (2005)
Neural cell adhesion molecule function is regulated by metalloproteinase-mediated ectodomain release
MV Hübschmann et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2005)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Genetic abnormalities and patterns of antigenic expression in multiple myeloma
G Mateo et al.
CLINICAL CANCER RESEARCH (2005)
The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system
H Chang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
CD56-positive small round cell tumor: Osseous plasmacytoma manifested in osteolytic tumors of the iliac bone and femora
T Kouno et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2005)
In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells
P Tassone et al.
CANCER RESEARCH (2004)
Prognostic significance of surface markers expressed in multiple myeloma: CD56 and other antigens
N Sahara et al.
LEUKEMIA & LYMPHOMA (2004)
Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma
N Sahara et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation
SA Ely et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma
IMS Dahl et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Share Paper
